Andrew G Nicholson

VU University Amsterdam, Amsterdamo, North Holland, Netherlands

Are you Andrew G Nicholson?

Claim your profile

Publications (396)2557.61 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Fibroblastic foci profusion on histopathology and severity of traction bronchiectasis on highresolution computed tomography (HRCT) have been shown to be predictors of mortality in patients with idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the relationship between fibroblastic foci (FF) profusion and HRCT patterns in patients with a histopathologic diagnosis of usual interstitial pneumonia (UIP), fibrotic non-specific interstitial pneumonia (NSIP) and chronic hypersensitivity pneumonitis (CHP). Methods The HRCT scans of 162 patients with a histopathologic diagnosis of UIP or fibrotic NSIP (n = 162) were scored on extent of groundglass opacification, reticulation, honeycombing, emphysema and severity of traction bronchiectasis. For each patient, a fibroblastic foci profusion score based on histopathologic appearances was assigned. Relationships between extent of fibroblastic foci and individual HRCT patterns were investigated using univariate correlation analysis and multivariate linear regression. Results Increasing extent of reticulation (P < 0.0001) and increasing severity of traction bronchiectasis (P < 0.0001) were independently associated with increasing FF score within the entire cohort. Within individual multidisciplinary team diagnosis subgroups, the only significant independent association with FF score was severity of traction bronchiectasis in patients with idiopathic pulmonary fibrosis (IPF)/UIP (n = 66, r2 = 0.19, P < 0.0001) and patients with chronic hypersensitivity pneumonitis (CHP) (n = 49, r2 = 0.45, P < 0.0001). Furthermore, FF score had the strongest association with severity of traction bronchiectasis in patients with IPF (r2 = 0.34, P < 0.0001) and CHP (r2 = 0.35, P < 0.0001). There was no correlation between FF score and severity of traction bronchiectasis in patients with fibrotic NSIP. Global disease extent had the strongest association with severity of traction bronchiectasis in patients with fibrotic NSIP (r2 = 0.58, P < 0.0001). Conclusion In patients with fibrotic lung disease, profusion of fibroblastic foci is strikingly related to the severity of traction bronchiectasis, particularly in IPF and CHP. This may explain the growing evidence that traction bronchiectasis is a predictor of mortality in several fibrotic lung diseases.
    BMC Medicine 09/2015; 13(1). DOI:10.1186/s12916-015-0479-0 · 7.25 Impact Factor

  • Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 09/2015; 10(9):1240-2. DOI:10.1097/JTO.0000000000000663 · 5.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on genetic studies, in particular, integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, (3) a new classification for small biopsies and cytology similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (4) a completely different approach to lung adenocarcinoma as proposed by the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (5) restricting the diagnosis of large cell carcinoma only to resected tumors that lack any clear morphologic or immunohistochemical differentiation with reclassification of the remaining former large cell carcinoma subtypes into different categories, (6) reclassifying squamous cell carcinomas into keratinizing, nonkeratinizing, and basaloid subtypes with the nonkeratinizing tumors requiring immunohistochemistry proof of squamous differentiation, (7) grouping of neuroendocrine tumors together in one category, (8) adding NUT carcinoma, (9) changing the term sclerosing hemangioma to sclerosing pneumocytoma, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, benign (with clear cell tumor as a variant) and
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 09/2015; 10(9):1243-60. DOI:10.1097/JTO.0000000000000630 · 5.28 Impact Factor

  • European Respiratory Journal 09/2015; 46(suppl 59):PA837. DOI:10.1183/13993003.congress-2015.PA837 · 7.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are both considered for blood-based mutation detection, but limited studies have compared them in a head-to-head manner. Using KRAS (Kirsten rat sarcoma viral oncogene homolog), we performed such a comparison in patients who underwent surgery for suspected lung cancer. We recruited 93 patients, including 82 with lung cancer and 11 with benign diseases of the lung. Mutations were detected in codons 12 and 13 of KRAS in DNA extracted from CTCs, plasma, and matched tumors or lung tissues with custom-designed coamplification at lower denaturation temperature (COLD)-PCR assays, high-resolution melt analysis (HRM), and commercial assays (Roche Cobas® KRAS mutation test and Qiagen Therascreen® pyrosequencing KRAS kit). With the Cobas mutation test, we identified KRAS mutations in 21.3% of tumors. Mutation analysis in matched CTC DNA and ctDNA samples by COLD-PCR/HRM assay revealed mutations in 30.5% (ctDNA) and 23.2% (CTC DNA) of patients with lung cancer. Combined results of different tests revealed KRAS-positive cases for 28% of tumors. The diagnostic sensitivity and specificity of KRAS mutation detection in tumors achieved with ctDNA was 0.96 (95% CI 0.81-1.00) and 0.95 (0.85-0.99), respectively. The diagnostic test performance was lower for CTC DNA, at 0.52 (0.34-0.73) and 0.88 (0.79-0.95). Our results support ctDNA as a preferential specimen type for mutation screening in thoracic malignancies vs CTC DNA, achieving greater mutation detection than either CTCs or limited amounts of tumor tissue alone. © 2015 American Association for Clinical Chemistry.
    Clinical Chemistry 08/2015; 61(10). DOI:10.1373/clinchem.2015.242453 · 7.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential treatment option for patients with cystic fibrosis. We aimed to assess the efficacy of non-viral CFTR gene therapy in patients with cystic fibrosis. We did this randomised, double-blind, placebo-controlled, phase 2b trial in two cystic fibrosis centres with patients recruited from 18 sites in the UK. Patients (aged ≥12 years) with a forced expiratory volume in 1 s (FEV1) of 50-90% predicted and any combination of CFTR mutations, were randomly assigned, via a computer-based randomisation system, to receive 5 mL of either nebulised pGM169/GL67A gene-liposome complex or 0·9% saline (placebo) every 28 days (plus or minus 5 days) for 1 year. Randomisation was stratified by % predicted FEV1 (<70 vs ≥70%), age (<18 vs ≥18 years), inclusion in the mechanistic substudy, and dosing site (London or Edinburgh). Participants and investigators were masked to treatment allocation. The primary endpoint was the relative change in % predicted FEV1. The primary analysis was per protocol. This trial is registered with, number NCT01621867. Between June 12, 2012, and June 24, 2013, we randomly assigned 140 patients to receive placebo (n=62) or pGM169/GL67A (n=78), of whom 116 (83%) patients comprised the per-protocol population. We noted a significant, albeit modest, treatment effect in the pGM169/GL67A group versus placebo at 12 months' follow-up (3·7%, 95% CI 0·1-7·3; p=0·046). This outcome was associated with a stabilisation of lung function in the pGM169/GL67A group compared with a decline in the placebo group. We recorded no significant difference in treatment-attributable adverse events between groups. Monthly application of the pGM169/GL67A gene therapy formulation was associated with a significant, albeit modest, benefit in FEV1 compared with placebo at 1 year, indicating a stabilisation of lung function in the treatment group. Further improvements in efficacy and consistency of response to the current formulation are needed before gene therapy is suitable for clinical care; however, our findings should also encourage the rapid introduction of more potent gene transfer vectors into early phase trials. Medical Research Council/National Institute for Health Research Efficacy and Mechanism Evaluation Programme. Copyright © 2015 Alton et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.
    07/2015; 22(9). DOI:10.1016/S2213-2600(15)00245-3
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interstitial lung disease in children (chILD) is rare, and most centres will only see a few cases/year. There are numerous possible underlying diagnoses, with specific and non-specific treatment possibilities. The chILD-EU collaboration has brought together centres from across Europe to advance understanding of these considerations, and as part of this process, has created standard operating procedures and protocols for the investigation of chILD. Where established consensus documents exist already, for example, for the performance of bronchoalveolar lavage and processing of lung biopsies, these have been adopted. This manuscript reports our proposals for a staged investigation of chILD, starting from when the condition is suspected to defining the diagnosis, using pathways dependent on the clinical condition and the degree of illness of the child. These include the performance of genetic testing, echocardiography, high-resolution CT, bronchoscopy when appropriate and the definitive investigation of lung biopsy, in order to establish a precise diagnosis. Since no randomised controlled trials of treatment have ever been performed, we also report a Delphi consensus process to try to harmonise treatment protocols such as the use of intravenous and oral corticosteroids, and add-on therapies such as hydroxychloroquine and azithromycin. The aim is not to dictate to clinicians when a therapeutic trial should be performed, but to offer the possibility to collaborators of having a unified approach when a decision to treat has been made. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
    Thorax 07/2015; DOI:10.1136/thoraxjnl-2015-207349 · 8.29 Impact Factor
  • Khin Thway · Simon Jordan · Cyril Fisher · Andrew G Nicholson ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary intrathoracic sarcomas are a rare, heterogeneous group of neoplasms that occur in the lung parenchyma, pleura and mediastinum. Although pathologically diverse, they frequently exhibit similar clinical and radiologic features, and hence accurate histopathological diagnosis is crucial for correct management and prognostication. The characterisation of sarcomas can be difficult as there is frequent overlap between the histological patterns of benign and malignant lesions, and between different malignant tumours and with non-mesenchymal neoplasms. This is particularly critical within the thorax, where many spindle cell neoplasms represent tumours of epithelial origin or metastatic disease. Immunohistochemistry and molecular genetic techniques are important ancillary contributors to histological interpretation, but several groups of tumours still lack reliable immunohistochemical markers or reproducible genetic changes. We review the pathology of the major types of intrathoracic sarcomas with reference to clinical factors, morphology, immunohistochemistry, and molecular genetics. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Histopathology 07/2015; DOI:10.1111/his.12771 · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating tumour cells (CTCs) attract a significant interest both in basic cancer research and in clinical oncology as a biomarker for diagnosis and prognosis of cancer. A number of techniques have been developed to trap and visualise CTCs.1 We postulated that antibody-independent approaches for collection of CTCs have a number of advantages, although subsequent effective visualisation of CTCs to distinguish them from surrounding white blood cells or non-cancerous epithelial cells is critical for their applicability for use in standard clinical settings.2 ,3 One potential solution is the usage of sensitive staining techniques such as recently developed ViewRNA in situ hybridisation by Affymetrix/Panomics. This approach is based on the use of specifically designed oligonucleotide probes against mRNA of genes of interest. These probes are hybridised to mRNA in fixed cells followed by binding of branched nucleic acids and fluorescent or chromogenic staining, which allow simultaneous identification of two or three targets, … [Full text of this article]
    Journal of clinical pathology 05/2015; 68(8). DOI:10.1136/jclinpath-2015-203112 · 2.92 Impact Factor

  • WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart., 4 edited by Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A. G., 04/2015: chapter Adenocarcinoma; IARC Press., ISBN: 9789283224365

  • WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart., 4 edited by Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A. G., 04/2015: chapter Variants of invasive adenocarcinoma; IARC Press., ISBN: 9789283224365

  • WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart., 4 edited by Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A. G., 04/2015: chapter Minimally invasive adenocarcinoma; IARC Press., ISBN: 9789283224365

  • WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart., Edited by Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A. G., 04/2015: chapter Preinvasive lesions; IARC Press., ISBN: 9789283224365
  • Eric Lim · Andrew G Nicholson · Simon Padley · Sanjay Popat ·

    04/2015; 3(4):328. DOI:10.1016/S2213-2600(15)00035-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic antibodies to Programmed Death receptor 1 (PD-1) and it's ligand PD-L1 show promising clinical results. Anti-PD-L1 immunohistochemistry (IHC) may be a biomarker to select patients more likely to respond to these treatments. However, the development of at least four different therapeutics, each with a different anti-PD-L1 IHC assay, has raised concerns amongst pathologists and oncologists alike. This paper reviews existing data on the IHC biomarker aspects of studies using these drugs in non-small cell carcinoma (NSCLC) and considers the challenges ahead, should these drug/IHC assay combinations reach routine practice. For each the known biomarker assays in development, there is a different monoclonal IHC antibody clone, produced by one of two diagnostics companies. Each test requires proprietary staining platforms and uses different definitions of a 'positive' test for PD-L1 expression, on tumour cells and, in one test, also on tumour infiltrating immune cells. There are still considerable gaps in our knowledge of the technical aspects of these tests, as well as of the biological implications and associations of PD-L1 expression in NSCLC, considering heterogeneity of expression, dynamic changes in expression and prognostic implications amongst other factors. The IASLC Pathology Committee raises the prospect of trying to harmonize and standardize testing for PD-L1 by IHC, at least at a technical level, but also, ideally, as a predictive marker, in order to facilitate availability of this test and a promising treatment for patients with NSCLC.
    Journal of Thoracic Oncology 03/2015; 10(7):1. DOI:10.1097/JTO.0000000000000526 · 5.28 Impact Factor
  • Source
    Erik Thunnissen · Birgit I Witte · Andrew G Nicholson ·

    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 02/2015; 10(1):e4. DOI:10.1097/JTO.0000000000000425 · 5.28 Impact Factor
  • S Sheard · A.G. Nicholson · L Edmunds · A.C. Wotherspoon · D M Hansell ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To review the clinical features of nine patients with pulmonary light-chain deposition disease (LCDD) and record their high-resolution CT (HRCT) and histopathological findings. Patients with a diagnosis of LCDD on lung biopsy specimen were retrospectively identified. The HRCT characteristics of nodules, cysts, and ancillary findings; change at follow-up; and histopathological findings were documented. Features common to all nine cases were thin-walled cysts. In seven cases, vessels traversing the cysts were identified. The majority of patients (8/9) had at least one pulmonary nodule. There was no zonal predominance of either cysts or nodules. The disease appeared stable in the majority of cases with no serial change in HRCT appearances (5/6 cases with follow-up data, mean duration 29 months). To the authors' knowledge, this is the largest series of pulmonary LCDD patients in the literature, and the first systematic assessment of HRCT findings. Pulmonary cysts are a unifying feature, usually with pulmonary nodules, and serial change on HRCT is unusual. Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
    Clinical Radiology 02/2015; 70(5). DOI:10.1016/j.crad.2015.01.002 · 1.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The rarity of thymomas and lack of multi-institutional studies have hampered therapeutic progress for decades. To overcome this, the members of the International Thymic Malignancy Interest Group created a worldwide retrospective database. This database was analyzed regarding the demographic and geographic distribution of thymomas and the impact of different variables on survival and recurrence. This study analyzed 4221 thymomas diagnosed between 1983 and 2012 with World Health Organization histotype information from the International Thymic Malignancy Interest Group database. Associations to survival and recurrence were studied by univariate and multivariate analyses. Type B2 thymoma is the most common (28%) and type A the least common (12%) histotypes. They are significantly more frequent in Europe and the United States than Asia. Type A and AB occur at significantly higher age than other thymomas (64 and 57 years, respectively). There are no differences in gender distribution. Stage is lower in type A (90% in stages I-II) and AB than B1 to B3 thymomas (38% of type B3 in stage III). In univariate analysis, recurrence is significantly less frequent among stage I/II tumors, in type A and AB (recurrence rates, 1-2%) than B1 to B3 thymomas (2-7%). Multivariate analysis reveals an impact of age, stage, and resection status on survival and recurrence, whereas for histology there is only a significant impact on recurrence. New findings are (1) geographic differences such as a lower incidence of type A and B2 thymoma in Asia; and (2) impact of stage and histology, the latter partially limited to early stage disease, on recurrence.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 02/2015; 10(2):367-372. DOI:10.1097/JTO.0000000000000393 · 5.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have analyzed levels of bombesin-positive neuroendocrine cells (NECs) in neuroendocrine cell hyperplasia of infancy (NEHI) and other childhood interstitial lung diseases (chILDs) in order to validate proposed histological criteria for NEHI and investigate its etiology. The extent of bombesin-positive cells within airway epithelium was analyzed in lung biopsies from 7 patients diagnosed with NEHI, including two previously classified as non-diagnostic, and other chILDs (n=64) with age range 1 month to 18 years. NECs were counted and calculated as a percentage of airways containing NECs, average percentage of NECs per airway, percentage of airways with >10% NECs and number of neuroendocrine bodies (NEBs). Correlation with age and gender was also undertaken. Patients with NEHI had the highest average percentage of bombesin-positive NECs per airway compared to other chILDs. However NEH was also seen in many other chILDs and appears to be most prominent in disorders associated with lung immaturity such as histological patterns associated with surfactant protein-related disorders and pulmonary interstitial glycogenosis. NEH may, to a degree, be a marker of airway immaturity rather than the direct cause of NEHI. This possibility is supported by the fact that the number of bombesin-positive NECs decreased with age in this cohort, independent of disease type. The average percentage of bombesin-positive NECs per airway appears to be the best histological criterion for assessing the extent of NECs in the context of NEHI. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Histopathology 02/2015; 67(4). DOI:10.1111/his.12672 · 3.45 Impact Factor

Publication Stats

25k Citations
2,557.61 Total Impact Points


  • 2015
    • VU University Amsterdam
      Amsterdamo, North Holland, Netherlands
  • 2003-2015
    • Imperial College London
      • Faculty of Medicine
      Londinium, England, United Kingdom
    • University of Auckland
      Окленд, Auckland, New Zealand
  • 1995-2015
    • Royal Brompton and Harefield NHS Foundation Trust
      • • Respiratory Medicine
      • • Department of Paediatrics
      Harefield, England, United Kingdom
  • 2011
    • University College London
      Londinium, England, United Kingdom
  • 2006-2011
    • National Heart, Lung, and Blood Institute
      Maryland, United States
  • 2003-2011
    • The Royal Marsden NHS Foundation Trust
      Londinium, England, United Kingdom
  • 2010
    • University Hospital of Parma
      Parma, Emilia-Romagna, Italy
  • 2009
    • Hampshire County Council
      Winchester, England, United Kingdom
  • 2008
    • The Heart Lung Center
      Londinium, England, United Kingdom
    • Vancouver General Hospital
      • Department of Radiology
      Vancouver, British Columbia, Canada
  • 2005-2008
    • Memorial Sloan-Kettering Cancer Center
      • Department of Pathology
      New York City, NY, United States
    • Erasmus Universiteit Rotterdam
      Rotterdam, South Holland, Netherlands
    • London School of Hygiene and Tropical Medicine
      • Department of Medical Statistics
      Londinium, England, United Kingdom
  • 2007
    • Bristol Hospital
      Bristol, Connecticut, United States
    • University of California, San Francisco
      • Division of Hospital Medicine
      San Francisco, CA, United States
  • 2004
    • King's College London
      Londinium, England, United Kingdom
    • The University of Edinburgh
      Edinburgh, Scotland, United Kingdom
    • Royal Berkshire NHS Foundation Trust
      Reading, England, United Kingdom
  • 2002-2004
    • The Bracton Centre, Oxleas NHS Trust
      Дартфорде, England, United Kingdom
    • WWF United Kingdom
      Londinium, England, United Kingdom
  • 2000-2002
    • Oxford University Hospitals NHS Trust
      • Nuffield Department of Clinical Laboratory Sciences
      Oxford, England, United Kingdom
  • 2001
    • Hirosaki University
      Khirosaki, Aomori, Japan
  • 1997
    • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
      Milano, Lombardy, Italy